Previous 10 | Next 10 |
Regeneron has a very strong pipeline consisting of treatments that can complement current cash cows (EYLEA and Dupixent) along with potential blockbusters. Even if EYLEA rapidly loses market share after its patent expirations, the growth from Dupixent and Libtayo will be more than eno...
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol PR Newswire TARRYTOWN, N.Y. , May 21, 2022 /PRNewswire/ -- Children already on other lipid-lowering therapies entered the ...
Regeneron just posted another impressive quarter for earnings (+16% YoY) and revenues (+17% YoY). Growth is set to slow after a one-time boost from its COVID antibody cocktail last year and an upcoming patent expiry for Eylea. A high-dose Phase 3 trial for Eylea and extensive road...
Sanofi (NASDAQ:SNY) (OTCPK:SNYNF) (GCVRX) received the U.S. regulatory approval for its Dupixent injection as a treatment for eosinophilic esophagitis, a condition of allergic inflammation of the esophagus, the U.S. Food and Drug Administration (FDA) announced on Frriday. According to Sanofi ...
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis PR Newswire TARRYTOWN, N.Y. and PARIS , May 20, 2022 /PRNewswire/ -- Dupixent is the first and only medicine indic...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...
Biopharmaceutical stocks have undergone a dramatic correction over the past six months, with the XBI declining by 45%. The decline was appropriate, given the number of companies that went public in 2021 with preclinical data and a valuation exceeding $1 billion. Not only would the...
Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur PR Newswire ROCHESTER, Minn. , May 17, 2022 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide rang...
High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair PR Newswire $75,000 Top Award Goes to 17-year-old Robert Sansone for pioneering invention to improve electric motor effic...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...